NOCILQ1 FY27
NOCIL Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹162P/E: 40.1Market Cap: ₹2.8K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →NOCIL expects revenue for FY27 to be in the range of Rs 1,400 to Rs 1,600 crores, based on the current pricing environment.
- →The company targets around 10% volume growth for the full year FY27.
- →EBITDA margin is expected to hover around 10% for FY27, supported by volume growth and operating leverage.
- →Export volumes aim to grow from around 33% currently to approximately 40-45% by FY28-29, indicating an increased focus on international markets.
- →Specialty segment, constituting 15% of the current topline, is expected to increase by an additional 5-10%, reaching around 20-25% of total revenue in 1-2 years.
- →New capacity from the TDQ plant is anticipated to start contributing from Q4 FY27, with ramp-up expected into FY28.
- →Overall volume growth projections remain positive despite transient supply-side challenges and geopolitical uncertainties.
Margin guidance
Category 3- Revenue guidance for FY27 is projected between Rs 1,400 to Rs 1,600 crores, reflecting continued growth.
- Volume growth for the full financial year is expected around 10%.
- EBITDA margins are anticipated around 10% for FY27, supported by a combination of volume growth, better product mix, and operating leverage.
- Q1 FY27 saw a 9% YoY volume growth and 20% YoY revenue growth; earnings (PAT) grew 61% YoY to Rs 28 crores.
- Anti-dumping duties (ADD) on certain products may bolster EBITDA, though the impact timeline is uncertain.
- New TDQ plant approvals may start contributing materially from Q4 FY27 into FY28, supporting further volume growth.
- Operating environment uncertainties exist but management remains optimistic about sustainable EBITDA run rate and continued earnings growth.
Overall, NOCIL expects disciplined execution with positive earnings trajectory driven by volume growth, product mix improvement, anti-dumping benefits, and operational efficiencies.
3 more insights locked — sign up free to unlock
Fundraise plans
- →The transcript and accompanying document do not mention any current or planned fundraising through debt or equity.
- →There is no discussion of new debt issuance or equity offerings during the Q1 FY27 earnings call or in the accompanying notes.
- →Promoter shareholding pledges were briefly mentioned, but the management declined to comment on the reasons or plans related to promoter pledging.
- →The focus is on operational growth, anti-dumping duty benefits, volume increases, specialty segment expansion, and cost control rather than on raising capital.
- →The company emphasizes maintaining prudent financial management but no explicit fundraising plans were disclosed.
Order book
The transcript does not explicitly mention the current or expected order book or pending orders for NOCIL Limited. However, the following points provide some related insights:
- The company faced temporary supply-side constraints and logistical challenges in Q1 FY27, causing a moderate 3% sequential volume decline and postponement of certain order commitments (Page 4).
- Customer demand remains healthy despite operational issues, and the company is confident of recovering deferred volumes in upcoming quarters (Page 4).
- Trial production at the new TDQ plant is underway, with sample approvals progressing and commercial supplies expected to ramp up starting Q4 FY27 and more significantly in Q1 FY28 (Pages 6 and 11).
- NOCIL is working closely with suppliers and logistics partners to normalize supplies and fulfill pending orders (Page 4).
No explicit quantitative data on order book size or pending orders is provided in the transcript.
Capex plans
Yes- →NOCIL is progressing well with a new Rs 130 crore investment in Dahej.
- →The Rs 130 crore investment is on track despite challenges due to the Middle East geopolitical situation.
- →Trial production at the new TDQ plant in Dahej has started, with sample approvals underway.
- →Commercial volumes from the TDQ plant are expected to start trickling in by Q4 FY27 and ramp up more significantly in Q1 FY28.
- →The investment in the TDQ plant aims to reinforce NOCIL's competitive market position.
- →Expansion focus is shifting towards the Specialty segment, expected to increase from the current 15% of revenue by an additional 5-10% over the next 1-2 years.
- →These expansions and specialty focus align with the strategic goal to diversify and grow product portfolio.
How does NOCIL rank vs peers in Chemicals & Petrochemicals?
Pro feature1NOCIL
Rev 3Mar 3
See full Chemicals & Petrochemicals sector rankings
How does NOCIL rank in Chemicals & Petrochemicals?
Compare NOCIL against every Chemicals & Petrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.